Short interest in Pfizer rose 6.8 million shares to 51.1 million in December. Market fears that generics will eat away at revenues at Big Pharma is not helping.
But, Pfizer is unique now. Its new heart drug, which management said was its blockbuster of the future, was pulled from late stage trials because is use caused more deaths that current therapies. How the company will fill that hole in its pipeline is a huge and concerning question.
Pfizer’s Lipitor, which brings in $12 billion a year, will also go "off patent" soon. Merck is also claiming that its drug Vytorin is superior to Lipitor for lowering cholesterol according to a large clinical trial.
Opps.
Douglas A. McInyre can be reached at [email protected]. He does not own securities in companies that he writes about.
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
